Loading clinical trials...
Loading clinical trials...
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Santen Inc.
Collaborators
NCT07024693 · Fuchs Endothelial Corneal Dystrophy, Fuchs
NCT04440280 · Fuchs Endothelial Corneal Dystrophy
NCT06966167 · Fuchs Endothelial Corneal Dystrophy, Cataract
NCT06425666 · Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy
NCT07217249 · Fuchs Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation
Stein Eye Institution UCLA
Los Angeles, California
Price Vision Group
Indianapolis, Indiana
Johns Hopkins University
Baltimore, Maryland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions